A
Alleviant Medical
Alleviant Medical is developing next-generation transcatheter technology designed to lift the clinical and economic burden of heart failure
About Alleviant Medical
Alleviant Medical is a pioneering medical device company focused on developing innovative interventional therapies for congestive heart failure (CHF). Operating within the healthcare and medical technology market, Alleviant Medical aims to address the significant unmet needs of patients suffering from CHF, a condition where the heart is unable to pump blood effectively, leading to severe health complications.
Read full description
The company's core product line consists of advanced medical devices designed to improve heart function and alleviate symptoms associated with CHF. By leveraging state-of-the-art technology and rigorous clinical research, Alleviant Medical seeks to provide effective, minimally invasive solutions that enhance patient outcomes and quality of life.
Alleviant Medical primarily serves healthcare providers, including hospitals, cardiology clinics, and specialized medical centers. The business model revolves around the development, regulatory approval, and commercialization of its proprietary medical devices. Revenue is generated through the sale of these devices to medical institutions and healthcare professionals, as well as potential partnerships and licensing agreements with larger medical technology companies.
At a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Austin, United States
- Employees
- 58
- Open positions
- None listed
- Dealroom signal
- 81.6/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Cardiology and cardiovascular, Non-Invasive medical devices and treatments, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Alleviant Medical.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jan 2025 | $90M | $360M | S3 Ventures · RiverVest Venture Partners · Longview Ventures · TMC Venture Fund | ↗ |
| LATE VCOther financing | Jan 2023 | $75M | $300M | Longview Ventures · TMC Venture Fund · Gilmartin Capital · S3 Ventures | ↗ |
Growth signals
Latest recorded traffic for Alleviant Medical is 1.6K monthly website visits, up 33.3% over the last three months. Alleviant Medical's team grew 5.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
MedTech Innovator
MassChallenge
Series B and later9 investors entered at this stage
Longview Ventures
TMC Venture Fund
Gilmartin Capital
S3 Ventures
RiverVest Venture Partners
ShangBay Capital
Vensana Capital
Gilde Healthcare
Omega Funds
Other known investors1 additional known investor
Texas Medical Center
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alleviant Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alleviant Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.